Abstract
Objective: Cytopathologists’ usage patterns for ‘atypia of undetermined significance’ (AUS) in thyroid fine-needle aspiration (FNA) are not well understood. AUS rates over a 5-year period were analyzed to quantify variability and identify correlations with experience and histologic outcomes. Study Design: A retrospective review of thyroid FNAs from a tertiary-care hospital from 2005 to 2009 was performed. Results were compiled for individual cytopathologists, stratified by year, and correlated with histologic outcomes. Results: Thyroid FNAs (5,327) were evaluated by 7 cytopathologists, with an overall AUS rate of 11.2%. The annual AUS rate remained relatively constant over this time period, though notable inter- and intrapathologist variability was seen. The AUS rate was significantly lower for those with cytopathology boards (10.3%) compared to those without (14.0%). There was no correlation between the AUS rate and cytopathologist experience or thyroid FNA volume. The AUS rate and malignant outcome were inversely related: the higher an individual’s AUS rate was, the lower the rate of malignancy for that AUS cohort was. Conclusions: Individual cytopathologist AUS rates were variable and often exceeded the recommended target of 7%. The application of recently published defined diagnostic criteria, along with directed cytopathologist feedback, may reduce observer variability and appropriately lower AUS utilization.
Journal Section:
Editor's choice
References
1.
Cibas ES, Ali SZ, NCI Thyroid FNA State of the Science Conference: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658–665.
[PubMed]
2.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology, ed 1. New York, Springer, 2010.
3.
Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD, Kim BW, Nosé V, Marqusee E, Larsen PR, Alexander EK: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer Cytopathol 2007;111:508–516.
[PubMed]
4.
Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations. Cancer 2007;111:306–315.
[PubMed]
5.
Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA: The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio: a proposed performance measure for reporting in the Bethesda System for Thyroid Cytopathology. Cancer Cytopathol 2011, DOI: 10.1002/cncy.20192.
6.
Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S: Implications of the proposed thyroid fine-needle aspiration category of ‘follicular lesion of undetermined significance’: a five-year multi-institutional analysis. Diagn Cytopathol 2009;37:710–714.
[PubMed]
7.
Nayar R, Ivanovic M: The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer Cytopathol 2009;117:195–202.
[PubMed]
8.
Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC: The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 2009;19:1215–1223.
[PubMed]
9.
Shi Y, Ding X, Klein M, Sugrue C, Matano S, Edelman M, Wasserman P: Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer Cytopathol 2009;117:298–304.
10.
Renshaw AA: Should ‘atypical follicular cells’ in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol 2010;118:186–189.
[PubMed]
11.
Jo VY, Stelow EB, Dustin SM, Hanley KZ: Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010;134:450–456.
[PubMed]
12.
Somma J, Schlecht NF, Fink D, Khader SN, Smith RV, Cajigas A: Thyroid fine needle aspiration cytology: follicular lesions and the gray zone. Acta Cytol 2010;54:123–131.
[PubMed]
13.
Marchevsky AM, Walts AE, Bose S, Gupta R, Fan X, Frishberg D, Scharre K, Zhai J: Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol 2010;38:252–259.
[PubMed]
14.
Vanderlaan PA, Marqusee E, Krane JF: Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated FNA be the preferred initial approach? Am J Clin Pathol 2011;135:770–775.
[PubMed]
15.
Faquin WC, Baloch ZW: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 2010;38:731–739.
[PubMed]
16.
Jing X, Knoepp SM, Roh MH, Hookim K, Placido J, Davenport R, Rasche R, Michael CW: Group consensus review minimizes the diagnosis of ‘follicular lesion of undetermined significance’ and improves cytohistologic concordance. Diagn Cytopathol 2011, DOI: 10.1002/dc.21702.
17.
Jing X, Roh MH, Knoepp SM, Zhao L, Michael CW: Minimizing the diagnosis of ‘follicular lesion of undetermined significance’ and identifying predictive features for neoplasia. Diagn Cytopathol 2010;39:737–742.
[PubMed]
18.
Juskevicius R, Zou KH, Cibas ES: An analysis of factors that influence the ASCUS/SIL ratio of pathologists. Am J Clin Pathol 2001;116:331–335.
[PubMed]
19.
Nascimento AF, Cibas ES: The ASC/SIL ratio for cytopathologists as a quality control measure: a follow-up study. Am J Clin Pathol 2007;128:653–656.
[PubMed]
20.
Abele JS, Levine RA: Diagnostic criteria and risk-adapted approach to indeterminate thyroid cytodiagnosis. Cancer Cytopathol 2010;118:415–422.
[PubMed]
21.
Koen TM, Mody DR, Scheiber-Pacht M, Fairley T, Thrall MJ: Limiting the use of atypical/inconclusive as a category in nongynecologic cytology specimens. Arch Pathol Lab Med 2010;134:1016–1019.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
